EF Hutton initiated coverage of Imunon with a Buy rating and $29 price target. The company is focused today on IL-12 immune therapy, initially in ovarian cancer, the analyst tells investors in a research note. The firm says IMNN-001 is a DNA-based immunotherapy for ovarian cancer that is advancing to a pivotal trial after “impressive” results in a Phase 2 study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- UPDATE – IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
- Imunon announces Ovarian Cancer R&D Day
- Imunon files to sell 5M shares of common stock for holders
- IMUNON to Host R&D Day on September 18th
- Mars buys Kellanova, Cardinal Health reports Q4 beat: Morning Buzz